Gainers
- rYojbaba (NASDAQ:RYOJ) stock moved upwards by 292.2% to $8.51 during Wednesday's after-market session. The company's market cap stands at $21.6 million.
- Mira Pharmaceuticals (NASDAQ:MIRA) stock moved upwards by 62.12% to $2.14. The market value of their outstanding shares is at $24.1 million.
- Nautilus Biotechnology (NASDAQ:NAUT) shares increased by 9.17% to $1.19. The market value of their outstanding shares is at $118.0 million.
- Adaptimmune Therapeutics (NASDAQ:ADAP) shares rose 8.41% to $0.2. The company's market cap stands at $42.4 million.
- Liminatus Pharma (NASDAQ:LIMN) shares increased by 6.61% to $1.29. The market value of their outstanding shares is at $36.5 million.
- Imunon (NASDAQ:IMNN) shares increased by 6.24% to $5.1. The company's market cap stands at $12.8 million.
Losers
- Genprex (NASDAQ:GNPX) shares declined by 21.9% to $0.66 during Wednesday's after-market session. The market value of their outstanding shares is at $10.8 million.
- Theriva Biologics (AMEX:TOVX) shares fell 18.31% to $0.69. The market value of their outstanding shares is at $4.1 million.
- Apollomics (NASDAQ:APLM) stock decreased by 16.42% to $16.3.
- Hyperfine (NASDAQ:HYPR) stock fell 11.37% to $1.95. The market value of their outstanding shares is at $161.0 million.
- Galectin Therapeutics (NASDAQ:GALT) shares decreased by 10.99% to $4.62. The market value of their outstanding shares is at $317.7 million.
- Prime Medicine (NASDAQ:PRME) stock decreased by 6.91% to $5.93. The market value of their outstanding shares is at $1.0 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
GALTGalectin Therapeutics Inc
$5.550.91%
GNPXGenprex Inc
$4.05-%
HYPRHyperfine Inc
$1.154.55%
IMNNImunon Inc
$3.983.38%
LIMNLiminatus Pharma Inc
$1.170.43%
MIRAMira Pharmaceuticals Inc
$1.45-%
NAUTNautilus Biotechnology Inc
$1.62-2.41%
PRMEPrime Medicine Inc
$3.971.28%
RYOJrYojbaba Co Ltd
$4.68-2.30%
TOVXTheriva Biologics Inc
$0.2748-0.36%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
